Kane Biotech Announces Publication of revyve Wound Gel Research in Prestigious International Wound Journal
WINNIPEG, Manitoba – Kane Biotech Inc., a biotechnology firm listed on the TSX Venture Exchange under the symbol KNE, has announced the publication of a significant scientific article on its revyve® Antimicrobial Wound Gel in the International Wound Journal. This peer-reviewed publication marks a key milestone for the company, providing independent validation of the gel's innovative properties and clinical potential.
Key Findings from the Published Study
The article, titled "Wound Healing Property of a Novel Thermo-Reversible Wound Gel With Lasting Antimicrobial and Antibiofilm Activity," is first-authored by Dr. Jeyachchandran Visvalingam, Internal R&D Leader at Kane Biotech, and includes contributions from researchers at the Miller School of Medicine, Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, University of Miami. The study highlights several critical aspects of the revyve gel:
- Thermo-Reversible Technology: The gel uniquely shifts from a low-viscosity liquid to a form-fitting gel at body temperature, then re-liquefies when cooled for easy and atraumatic removal, enhancing patient comfort and reducing tissue damage during dressing changes.
- Broad-Spectrum Efficacy: revyve demonstrated potent activity against a wide range of wound-related pathogens, including Staphylococcus aureus and Pseudomonas aeruginosa, achieving a 99.99% to 99.9999% reduction in bacterial counts within just 30 minutes.
- Sustained Antimicrobial Action: In vitro testing showed sustained activity for up to seven days, which could potentially decrease the frequency of dressing changes, thereby improving clinical efficiency and patient outcomes.
- Safety Validation: The gel's safety and non-cytotoxicity were confirmed through rigorous biocompatibility testing and a porcine wound-healing study, underscoring its suitability for clinical use.
Regulatory Approvals and Commercial Impact
revyve Antimicrobial Wound Gel has received U.S. FDA 510(k) clearance and Health Canada approval, positioning it as a commercially available product in North America. Dr. Robert Huizinga, Interim CEO of Kane Biotech, emphasized the importance of this publication, stating, "Having our research published in the International Wound Journal underscores the scientific rigor behind revyve technology and provides independent, peer-reviewed validation of the gel’s safety, in vitro performance, and clinical potential. Recognition in such a respected global wound-care publication strengthens our credibility with clinicians, regulators, and commercial partners, reinforcing our commitment to advancing evidence-based solutions that improve patient outcomes."
About Kane Biotech and the International Wound Journal
Kane Biotech specializes in developing and commercializing novel wound care treatments that target biofilms, a major contributor to antibiotic resistance in wounds. The company's revyve product line, which includes the gel, spray, and cleanser, is designed to address both biofilms and wound bacteria, with all products holding U.S. FDA 510(k) clearance. The International Wound Journal is a leading peer-reviewed scientific journal focused on wound care research, publishing studies that advance knowledge in prevention, treatment, and management.
For more information, Kane Biotech encourages stakeholders to visit their websites at revyvegel.com or revyvegel.ca, and to follow updates through their social media channels and email distribution list.
